Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
式(I)的化合物或其药学上可接受的盐,是GPCR激动剂,可用于治疗肥胖症和糖尿病。
Piperidine GPCR agonists
申请人:Prosidion Limited
公开号:EP2383270A1
公开(公告)日:2011-11-02
GPCR AGONISTS
Compounds of formula (I):
or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2547339A1
公开(公告)日:2013-01-23
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
申请人:Eickelmann Peter
公开号:US20130109703A1
公开(公告)日:2013-05-02
The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
[EN] PIPERIDINE GPCR AGONISTS<br/>[FR] AGONISTES DE GPCR DE TYPE PIPÉRIDINE
申请人:PROSIDION LTD
公开号:WO2008081205A1
公开(公告)日:2008-07-10
[EN] Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. [FR] L'invention concerne des composés représentés par la formule (I) : ou des sels acceptables du point de vue pharmaceutique de ceux-ci, qui sont des agonistes de GPCR et s'utilisent pour le traitement de l'obésité et du diabète.